Clinical value of pre-transplant minimal residual disease in childhood lymphoblastic leukaemia: the results of the French minimal residual disease-guided protocol.

Date publication

mai 2014

Auteurs

Membres identifiés du Cancéropôle Est :
Dr POCHON Cécile

Tous les auteurs :
Gandemer V, Pochon C, Oger E, Dalle JH, Michel G, Schmitt C, de Berranger E, Galambrun C, Cave H, Cayuela JM, Grardel N, Macintyre E, Margueritte G, Mechinaud F, Rorhlich P, Lutz P, Demeocq F, Schneider P, Plantaz D, Poiree M, Bordigoni P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/24479958

Résumé

Minimal residual disease (MRD) is a major predictive factor of the cure rate of acute lymphoblastic leukaemia (ALL). Haematopoietic cell transplantation is a treatment option for patients at high risk of relapse. Between 2005 and 2008, we conducted a prospective study evaluating the feasibility and efficacy of the reduction of immunosuppressive medication shortly after a non-ex vivo T depleted myeloablative transplantation. Immunoglobulin (Ig)H/T-cell receptor MRD 30 d before transplant could be obtained in 122 of the 133 cases of high-risk paediatric ALL enrolled. There were no significant demographic differences except remission status (first or second complete remission) between the 95 children with MRD /=10(-3) . Multivariate analysis identified sex match and MRD as being significantly associated with 5-year survival. MRD >/=10(-3) compromised the 5-year cumulative incidence of relapse (43.6 vs. 16.7%). Complete remission status and stem cell source did not modify the relationship between MRD and prognosis. Thus, pre-transplant MRD is still a major predictor of outcome for ALL. The MRD-guided strategy resulted in survival for 72.3% of patients with MRD/=10(-3).

Référence

Br J Haematol. 2014 May;165(3):392-401